Gyros Protein Technologies and Cygnus Technologies Sign Licensing and Supply Agreement

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale
immunoassays and leading provider of peptide synthesizers and reagents,
and Cygnus Technologies, the leading assay and services provider for the
detection and characterization of impurities in biopharmaceuticals,
today announced they have signed a licensing and supply agreement.

Under the agreement, Cygnus Technologies will supply Gyros Protein
Technologies with its proprietary reagents for host cell protein
analysis, enabling the development of new Gyrolab® immunoassay kits and
applications to further support customers working in biotherapeutics
development and manufacturing. Gyros Protein Technologies has
established expertise in bioprocess development, through its Gyrolab
platforms and Gyrolab ready-to-use kits for CHO-HCP, Protein A impurity
analyses, and IgG titer determinations. Gyrolab users carrying out
impurity analysis will now also benefit from the products and expertise
provided by Cygnus Technologies.

As the global leader in ELISA kits for bioprocess impurity analysis,
Cygnus Technologies will also assist Gyrolab users in developing custom,
process-specific antibodies, or in running orthogonal methods for
antibody and impurity characterization.

Dan Calvo, CEO and president, Gyros Protein Technologies, said: “The
agreement with Cygnus Technologies forms part of our strategy to
continue to support customers with high quality bioanalytical solutions,
and to increase productivity in the development and manufacturing of
biotherapeutics. Cygnus Technologies’ offering complements our current
portfolio, and the partnership will enable us to increase our support to
bioprocess customers.”

Ken Hoffman, president of Cygnus Technologies, said: “This
collaboration with Gyros Protein Technologies will give customers
looking for automated solutions the opportunity to automate our
well-characterized antibodies and antigens on the Gyrolab platforms.
Those same customers can also access custom antibody services along with
state-of-the-art orthogonal analytical methods developed at Cygnus
Technologies.”

ENDS

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005660/en/

Leave a Comment